伊马替尼治疗慢性粒细胞性白血病疗效观察  

Observation of curative effect of treatment for chronic myeloid leukemia with Imatinib

作　　者：杨文忠[1] 葛秀清[1] 甘欣锦[1] 贾新颜[1] 

机构地区：[1]上海同济大学附属东方医院,上海200120

出　　处：《现代中西医结合杂志》2008年第25期3900-3901,3952,共3页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的观察伊马替尼(Imatinib)治疗慢性粒细胞性白血病(CML)的近期疗效和安全性。方法28例CML患者均予伊马替尼400或600 mg/d一次性餐后顿服,常规体检,用药后血液学取得完全缓解后择期复查骨髓、Ph染色体和/或BCR-ABL基因。结果随访结束时,血液学完全缓解率61%(17/28),部分缓解率11%,总有效率71%,绝大多数为轻度不良反应,多可耐受。结论伊马替尼治疗CML有效、安全,但远期疗效需进一步观察。Objective It is to observe the early curative effect and the security of the treatment for chronic myelocytic leukemia（CML） with Imatinib. Methods 28 patients with CML were given Imatinib 400 or 600 mg/d orally after a meal once a day. All the patients were accepted normal physical examination before imatinib administration. Bone marrow, Ph chromosome and/or BCR- ABL fusion gene were detected again in a selective time after complete remission of hematology. Results After a 12 - 24 - month period of follow-up, complete remission rate of hematology was 61% （ 17/28）, partial remission rate of hematology was 11% , and ＂the ＂total effective rate were 71%. The majority of ＂the patients encountered light to mild non-hematologic adverse effect which was well tolerated. Conclusion Imatinib has an effective and safe curative effect on CML, but the long term curative effect should be observed further.

关 键 词：慢性白血病 髓样 伊马替尼 费城染色体 

分 类 号：R733.72[医药卫生—肿瘤] R979.1[医药卫生—临床医学]